2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOWill not start
The primary objective is to investigate feasibility (number of successful automated venipunctures) and safety (number of adverse events and adverse device events). Secondary objectives are to determine subject's pain experience, duration of…